Stanford researchers identify a natural molecule that suppresses appetite like Ozempic

Researchers at Stanford Medicine say they have identified a naturally occurring molecule in the body that appears to suppress appetite and reduce body weight through mechanisms similar to blockbuster drugs like Ozempic — but, in early findings, without triggering some of the common side effects associated with that class of medication.

GLP-1 receptor agonist drugs, including semaglutide (sold as Ozempic and Wegovy) and related compounds, have transformed obesity treatment in recent years by mimicking a gut hormone that signals fullness to the brain, helping patients eat less and lose substantial weight. Their rapid rise has also brought well-documented downsides for a significant share of patients, including nausea, vomiting, and other gastrointestinal side effects that lead some to discontinue treatment, along with concerns about loss of lean muscle mass alongside fat.

The newly identified molecule is naturally produced by the body rather than being a synthetic drug, and Stanford researchers say early work suggests it activates weight-regulating pathways that overlap with, but are not identical to, those targeted by GLP-1 drugs. That distinction is significant: because the molecule works through a somewhat different mechanism, researchers are hopeful it could offer meaningful appetite suppression and weight reduction while sidestepping some of the gastrointestinal side effects that make GLP-1 drugs difficult for a subset of patients to tolerate long-term.

The research is still at a relatively early stage, and Stanford scientists have been cautious about the timeline to any clinical application. Discoveries of naturally occurring molecules with drug-like effects typically require years of further research — first to fully characterize the mechanism, then to test synthetic or stabilized versions of the molecule in animal models, and eventually in human clinical trials — before any potential treatment could reach patients. Many promising early-stage metabolic discoveries do not ultimately translate into approved therapies, and researchers caution against assuming the molecule will become a marketed drug.

Even so, the finding lands at a moment of intense scientific and commercial interest in the next generation of obesity treatments. The success of GLP-1 drugs has triggered a wave of investment from pharmaceutical companies racing to develop follow-on treatments that match their weight-loss efficacy while improving on tolerability, cost, or convenience — including oral formulations, longer-acting injectables, and drugs targeting different hormonal pathways altogether. A naturally occurring molecule with a favorable side-effect profile would be a notable addition to that pipeline if it holds up under further study.

Obesity researchers not involved in the work note that identifying a molecule's effect in early studies is only the first of many steps, and that questions about dosing, long-term safety, and whether weight loss is sustained after stopping treatment — a persistent challenge with existing GLP-1 drugs, which often see patients regain weight after discontinuation — will need to be answered before the discovery could meaningfully change clinical practice.

Stanford researchers say further studies are planned to better understand how the molecule interacts with the brain's appetite-regulating circuits, and whether a stable, deliverable version could eventually be developed for testing in humans.